ForumIAS LATEST
- 08 June | Sociology Optional Strategy Session with AIR 10 Ujjwal Priyank Click Here to register →
- 08 June | Geography Optional Strategy Session with AIR 39 Rohin Kumar Click Here to register →
- 09 June | Ethics+ Class #1 + Case Studies Workshop by Mr. Ayush Sinha | Click Here to register →
News: Pharmaceutical company Pfizer announced mid-stage trial results of berobenatide, an experimental once-monthly anti-obesity and diabetes drug.
About Berobenatide – New Obesity Drug
- Berobenatide is an experimental anti-obesity and diabetes drug that is designed to be administered as a once-monthly injection.
- Developed by: It has been developed by Pfizer.
- Working Mechanism:
- GLP-1 Receptor: Berobenatide is a GLP-1 (glucagon-like peptide-1) weight-loss therapy that mimics the gut hormone GLP-1 to regulate blood sugar, slow stomach emptying, and reduce appetite.
- Appetite & Digestion: The drug helps reduce appetite and slows stomach emptying, which supports weight management and blood sugar regulation.
- Extended Circulation Design: The drug has been engineered to remain in circulation much longer than conventional GLP-1 therapies, allowing sustained activation of GLP-1 receptors throughout the month.
- Dosing: Patients would initially receive weekly doses before transitioning to a single injection every month, reducing the number of injections from 52 per year to 12 per year.
- Efficacy: Patients without diabetes lost up to 12.3% of their body weight, and weight loss continued after the shift to monthly dosing.
- Limitation: Experts have stated that long-term data, particularly on cardiovascular outcomes, are still needed.
- Significance: Less frequent dosing may reduce treatment fatigue, improve treatment persistence, and help patients remain on therapy for longer periods.
- Other Obesity Drug:
- Semaglutide (branded as Ozempic/Wegovy) – developed by Novo Nordisk
- Tirzepatide (branded as Mounjaro/Zepbound) – developed by Eli Lilly
